S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
NASDAQ:SVRA

Savara Stock Forecast, Price & News

$1.30
0.00 (0.00%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.28
$1.32
50-Day Range
$1.04
$1.36
52-Week Range
$1.03
$3.58
Volume
138,235 shs
Average Volume
278,047 shs
Market Capitalization
$148.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.99
30 days | 90 days | 365 days | Advanced Chart
Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.


Savara logo

About Savara

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Headlines

Form 10-Q Savara Inc For: Sep 30 - StreetInsider.com
November 12, 2021 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SVRA
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$260 thousand
Book Value
$1.19 per share

Profitability

Net Income
$-49.62 million
Pretax Margin
-4,544,659.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
108,437,000
Market Cap
$148.03 million
Optionable
Optionable

Company Calendar

Last Earnings
11/12/2021
Today
1/16/2022
Next Earnings (Estimated)
2/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

210th out of 1,410 stocks

Pharmaceutical Preparations Industry

87th out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Savara (NASDAQ:SVRA) Frequently Asked Questions

Is Savara a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara
or view top-rated stocks.

How has Savara's stock price been impacted by COVID-19 (Coronavirus)?

Savara's stock was trading at $2.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SVRA shares have decreased by 44.9% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19
.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Friday, February 11th 2022.
View our earnings forecast for Savara
.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) announced its earnings results on Friday, November, 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.02.
View Savara's earnings history
.

What price target have analysts set for SVRA?

3 brokers have issued 1-year price objectives for Savara's stock. Their forecasts range from $4.00 to $7.00. On average, they expect Savara's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 323.1% from the stock's current price.
View analysts' price targets for Savara
or view top-rated stocks among Wall Street analysts.

Who are Savara's key executives?

Savara's management team includes the following people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46) (LinkedIn Profile)
  • Yuri Pikover, Independent Director (Age 56)

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.30.

How much money does Savara make?

Savara has a market capitalization of $148.03 million and generates $260 thousand in revenue each year.

What is Savara's official website?

The official website for Savara is www.savarapharma.com.

Where are Savara's headquarters?

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848, via email at [email protected], or via fax at 858-552-0876.


This page was last updated on 1/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.